Comparing Raman Spectroscopy to Flow Cytometry for Detecting Leukemia
Raman Spectroscopy Compared to Flow Cytometry as a Method for Assessing Measurable Residual Disease in Patients With Acute Lymphoblastic Leukemia
This study is testing if a new light-based method called Raman spectroscopy can better detect leftover leukemia cells in patients with acute lymphoblastic leukemia compared to the usual flow cytometry method.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 2 Years to 70 Years |
| Sex | All |
| Sponsor | Hospital Regional de Alta Especialidad del Bajio Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (León, Guanajuato) |
| Trial ID | NCT06291428 on ClinicalTrials.gov |
What this trial studies
This study evaluates the presence of measurable residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) by comparing the standard method of flow cytometry with a novel approach using Raman spectroscopy. Flow cytometry, while commonly used, has limitations in sensitivity and standardization, prompting the exploration of Raman spectroscopy as a potential alternative. This technique utilizes the inelastic scattering of light to analyze the biochemical composition of biological samples, which may improve MRD detection. The study aims to determine if Raman spectroscopy can provide a more effective means of MRD evaluation in ALL patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with acute lymphoblastic leukemia who require MRD determination.
Not a fit: Patients who do not have acute lymphoblastic leukemia will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a more accurate and standardized method for MRD detection in leukemia patients, potentially improving prognosis and treatment outcomes.
How similar studies have performed: While flow cytometry is a well-established method, the use of Raman spectroscopy for MRD detection is novel and has not been widely tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with ALL for whom MRD determination is clinically necessary will be included in the study. Exclusion Criteria: * Patients without ALL
Where this trial is running
León, Guanajuato
- Hospital Regional Alta Especialidad Bajio — León, Guanajuato, Mexico (Recruiting)
Study contacts
- Study coordinator: Lauro F Amador Medina, PhD
- Email: lafab2013@gmail.com
- Phone: 4772697907
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.